TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Update

Key Points

• TriSalus Life Sciences experienced a significant increase in short interest, rising by 78.2% to 918,500 shares as of September 30, indicating growing bearish sentiment among investors.
• Analysts have given the stock an average rating of "Buy" with a target price of $10.90, despite two analysts recently downgrading their ratings to "sell."
• TriSalus reported a loss of $0.27 per share in its last earnings report, falling short of analyst expectations, although it exceeded revenue projections with $11.21 million.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 918,500 shares, an increase of 78.2% from the September 15th total of 515,400 shares. Approximately 5.7% of the company's shares are short sold. Based on an average daily volume of 101,200 shares, the short-interest ratio is currently 9.1 days. Based on an average daily volume of 101,200 shares, the short-interest ratio is currently 9.1 days. Approximately 5.7% of the company's shares are short sold.

Analysts Set New Price Targets

TLSI has been the subject of a number of analyst reports. Wall Street Zen lowered shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research report on Sunday, September 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of TriSalus Life Sciences in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $10.90.

TriSalus Life Sciences Stock Performance

TriSalus Life Sciences stock opened at $5.28 on Tuesday. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $5.88. The firm has a 50 day moving average price of $4.77 and a 200 day moving average price of $5.00. The company has a market cap of $263.30 million, a price-to-earnings ratio of -4.47 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). The business had revenue of $11.21 million for the quarter, compared to the consensus estimate of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. Sell-side analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. purchased a new position in shares of TriSalus Life Sciences in the 1st quarter valued at $55,000. Goldman Sachs Group Inc. purchased a new position in TriSalus Life Sciences in the 1st quarter valued at about $187,000. Gilder Gagnon Howe & Co. LLC grew its stake in shares of TriSalus Life Sciences by 32.1% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company's stock valued at $5,957,000 after acquiring an additional 265,618 shares in the last quarter. Geode Capital Management LLC increased its position in shares of TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company's stock worth $2,480,000 after acquiring an additional 235,627 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of TriSalus Life Sciences by 1.8% in the second quarter. Bank of America Corp DE now owns 188,906 shares of the company's stock worth $1,030,000 after acquiring an additional 3,374 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.